Please login to the form below

Not currently logged in
Email:
Password:

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

Amgen has appointed Wanda Austin to its board of directors and as a member of its audit committee and corporate responsibility and compliance committee.

Austin most recently retired from her role as president and chief executive officer of space programme The Aerospace Corporation, where she has served from 2008 to 2016.

Robert Bradway, chairman and chief executive officer, Amgen, said: “We are pleased to welcome Dr Wanda Austin to Amgen’s board.

“Wanda’s deep experience in long-cycle technology and engineering settings and her senior leadership experience will be invaluable to Amgen.”

The addition of Austin will see Amgen’s board comprise of 14 directors, 13 of whom are independent of the company.

2nd November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics